CytoSorbents Reports Preliminary Fourth Quarter and Full Year 2020 Revenue Preliminary Full Year and Q4 2020 Product Sales were $39.5 million and $11.5 million, respectively, representing growth of 73% and 74%, respectiv

CytoSorbents Reports Preliminary Fourth

Quarter and Full Year 2020 Revenue

Preliminary Full Year and Q4 2020 Product

Sales were $39.5 million and $11.5 million, respectively, representing growth of 73% and 74%, respectively, over the corresponding

prior periods. Cumulative CytoSorb treatments surpassed 121,000.

MONMOUTH JUNCTION, NJ - January

12, 2021 - CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb

blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world, pre-announces

preliminary unaudited fourth quarter 2020 and full-year 2020 results ahead of filing its Form 10-K.

Preliminary 2020 Financial Highlights:

The Company expects to announce the

Dr. Phillip Chan, Chief Executive Officer

of CytoSorbents stated, "Our record financial performance in 2020 reflects the underlying strength of our core businesses

in critical care and cardiac surgery, aided by broad-based demand for CytoSorb as a powerful therapy to treat cytokine storm and

hyperinflammation in mechanically ventilated COVID-19 patients. By leveraging our existing businesses, with new opportunities such

as liver disease and the removal of blood thinners in cardiothoracic surgery, we believe 2021 will be another year of strong growth.

We plan to provide more detail on the year ahead in a stockholder's letter later this month."

Corporation (NASDAQ: CTSO)

Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb

is approved in the European Union with distribution in 67 countries around the world, as an extracorporeal cytokine adsorber

designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive

inflammation, organ failure and death in common critical illnesses. These are conditions where the risk of death is extremely

high, yet no effective treatments exist. CytoSorb is also being used during and after cardiac surgery to remove inflammatory

mediators that can lead to post-operative complications, including multiple organ failure. CytoSorb has been used in more

than 121,000 human treatments to date. CytoSorb has received CE-Mark label expansions for the removal of bilirubin (liver disease),

myoglobin (trauma) and both ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorb has also received

FDA Emergency Use Authorization in the United States for use in critically ill COVID-19 patients with imminent or confirmed

respiratory failure, in defined circumstances. CytoSorb has also been granted FDA Breakthrough Designation for the removal

of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery.

purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from

blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract,

and other funding of more than $38 million from DARPA, the U.S. Department of Health and Human Services (HHS), the National Institutes

of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special Operations

Command (SOCOM), Air Force Material Command (USAF/AFMC), and others. The Company has numerous products under development based

upon this unique blood purification technology protected by many issued U.S. and international patents and multiple applications

pending, including ECOS-300CY , CytoSorb-XL , HemoDefend-RBC , HemoDefend-BGA , VetResQ , K+ontrol ,

ContrastSorb, DrugSorb, and others. For

more information, please visit the Company's websites at www.cytosorbents.com and www.cytosorb.com or follow

us on Facebook and Twitter.

release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private

Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our

plans, objectives, representations and contentions, including, but not limited to, statements regarding our plans to leverage

our existing business for future growth and to deliver a stockholders letter, and are not historical facts and typically are identified

by use of terms such as "may," "should," "could," "expect," "plan,"

"anticipate," "believe," "estimate," "predict," "potential," "continue"

and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking

statements in this press release represent management's current judgment and expectations, but our actual results, events

and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute

to such differences include, but are not limited to, risks discussed in our Annual Report on Form 10-K, filed with the SEC on

March 5, 2020, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, and in

the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested

parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking

statements, particularly in light of the current coronavirus pandemic, where businesses can be impacted by rapidly changing state

and federal regulations, as well as the health and availability of their workforce. We undertake no obligation to publicly update

or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required

under the Federal securities laws.

Cytosorbents Contact:

Investor Relations Contact:

Public Relations Contact:

Rubenstein Public Relations